![Wilms' tumor stained with WT1 [rWT1/857] Antibody.](https://biocare.net/wp-content/uploads/3238_WT1_Wilms-tumor.jpg "Wilms' tumor stained with WT1 [rWT1/857] Antibody.")
WT1 [rWT1/857]
$345.00 – $676.00
Description
Product Description
WT1 is a gene involved in the induction of Wilms’ tumor. In normal human tissues, WT1 mRNA has been observed in kidney, spleen and gonadal ridge mesoderm (1). WT1 expression has also been observed in sertoli cells of testes and in granulosa cells of the ovary. In tumors, WT1 has been demonstrated in Wilms’ tumors and in the majority of mesotheliomas (nuclear and paranuclear staining) (2). WT1 has also been demonstrated in the majority of acute leukemias, but not in cells from chronic myelogenous leukemia (3). Cytoplasmic staining has been observed in some cases of adenocarcinoma and may represent crossreactivity with an epitope unrelated to WT1 (2).
Specifications
Specifications
| Intended Use | |
|---|---|
| By Letter | |
| Antigen | |
| Clone | |
| Isotype | |
| Positive Control | |
| Species Reactivity | |
| Source |
Datasheets & SDS
References
1. Wilm B, Muñoz-Chapuli R. The Role of WT1 in Embryonic Development and Normal Organ Homeostasis. Methods Mol Biol.
2016;1467:23-39.
2. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung
adenocarcinoma. Am J Surg Pathol. 2003 Aug;27(8):1031-51.
3. Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia. 2003 Jul;17(7):1301-12.
4. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
5. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.
Related products
B
